FDA Proposes Excluding GLP-1 from Compounding List

The FDA proposed April 30 to exclude Novo Nordisk and Eli Lilly obesity and diabetes active pharmaceutical ingredients from the compounding allowance list, citing lack of clinical need for compounded GLP-1 products.